Lung cancer is the leading cause of cancer-related death worldwide, exceeding that attributable to breast, prostate, colon, kidney, and liver cancer combined. Recently, the identification of recurrent genetic alterations has led to molecularly-targeted therapies for a subset of lung cancers. Activating mutations in RAS-family oncoproteins are among the most frequent genomic alterations in non-small cell lung cancer (NSCLC) and are mutated in up to 30% of all human cancers. Despite intensive efforts to target KRAS, no molecularly targeted therapies exist and patients still receive cytotoxic and largely ineffective chemotherapies. Indeed, direct pharmacological inhibition of mutant RAS has remained difficult, and targeting of other downstream RAS effectors, in particular the MAPK pathway, has been ineffective due to toxicities and adaptive drug resistance mechanisms. In response to the urgent need for developing strategies to target KRAS mutant cancers, this Program Project has explored that action of agents that target the RAS network, producing insights into adaptive resistance mechanisms and characterizing the first direct KRAS mutant inhibitors. Our project, together with Rosen (RP2), established that the rebound in MAPK signaling occurring after MEK inhibition is responsible for adaptive drug resistance and, though a functional genomics screen, identified upstream activation of the FGFR1 signaling axis as contributing to this effect. Consequently, FGFR1 is an induced dependency produced by MEK inhibition and therapeutic approaches targeting MEK and FGFR1 are being developed as a clinical strategy for treating KRAS mutant lung cancers. Our renewal builds on these successes towards the goal of identifying additional combinatorial strategies targeting KRAS mutant cancers. Expanding upon extensive preliminary data, we study effectors required for tumor maintenance in KRAS driven lung cancers treated with MAPK or KRAS inhibitors, explore novel and existing strategies for combinatorial target inhibition, and examine the interplay between pathway inhibition, tissue and genomic context, and immune surveillance. The project builds on existing collaborations and incorporates innovative technology and mouse modeling systems into the program; it interacts with, and benefits from, each of the other projects and cores. Successful completion of the proposed work will provide critical insights into RAS signaling and form a foundation for bringing targeted therapy for KRAS mutant lung cancer into the clinical arena.

Public Health Relevance

Although KRAS is the most frequently mutated oncogene in human lung cancer and represents a compelling therapeutic target, lung cancer patients harboring KRAS mutant cancers are currently treated with ineffective and toxic chemotherapies. This proposal uses optimized genetic and modeling platforms to reveal mechanisms of signaling plasticity and immune surveillance following treatment with RAS network inhibitors with the goal of identifying molecular targeted and/or immune oncology agents that could be used in combination to effectively treat KRAS mutant lung cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA129243-13
Application #
9999418
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2007-07-01
Project End
2023-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
13
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Gao, Yijun; Chang, Matthew T; McKay, Daniel et al. (2018) Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discov 8:648-661
Arbour, Kathryn C; Jordan, Emmett; Kim, Hyunjae Ryan et al. (2018) Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 24:334-340
Gallant, Jean-Nicolas; Lovly, Christine M (2018) Established, emerging and elusive molecular targets in the treatment of lung cancer. J Pathol 244:565-577
Hellmann, Matthew D; Nathanson, Tavi; Rizvi, Hira et al. (2018) Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33:843-852.e4
Yao, Zhan; Gao, Yijun; Su, Wenjing et al. (2018) RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med :
Suzawa, Ken; Offin, Michael; Lu, Daniel et al. (2018) Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin Cancer Res :
Yu, Helena A; Planchard, David; Lovly, Christine M (2018) Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book :726-739
Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel et al. (2018) Differential Effector Engagement by Oncogenic KRAS. Cell Rep 22:1889-1902
Ruscetti, Marcus; Leibold, Josef; Bott, Matthew J et al. (2018) NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 362:1416-1422
Du, Zhenfang; Lovly, Christine M (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17:58

Showing the most recent 10 out of 188 publications